PD-L1 expressing hematopoietic stem cells and uses
AssigneeChildren's Medical Center Corporation
InventorPaolo Fiorina
Life of this patent
Estimating the term…
Abstract
Embodiments disclosed here provide engineered modified hematopoietic stem cells (HSCs), artificially prostaglandin E2 (PGE2)-stimulated HSCs, compositions comprising these HSCs, methods of using these modified HSCs for treating autoimmune diseases and disorders and for suppressing the immune system. In particular, the engineered modified HSCs or PGE2-stimulated HSCs express the surface marker, programmed cell death-1 ligand 1 (PD-L1).
Claims19
A method of treating Type 1 diabetes (T1D) by suppressing immune-mediated destruction of pancreatic islet β-cells, the method comprising:
- administering to a subject with T1D a composition comprising a population of genetically modified PD-L1+-expressing hematopoietic stem cells (HSCs) in an amount effective to suppress immune-mediated destruction of pancreatic islet β-cells, wherein the subject is not administered another immunosuppressive therapy.
A method of treating the onset of pediatric Type 1 diabetes (T1D), the method comprising:
- administering to a pediatric subject with new onset T1D a therapeutically effective amount of a composition comprising a population of genetically modified PD-L1+-expressing hematopoietic stem cells (HSCs), wherein the pediatric subject is not administered another immunosuppressive therapy.
A method of treating the onset of adult Type 1 diabetes (T1D), the method comprising:
- administering to an adult subject with new onset T1D a therapeutically effective amount of a composition comprising a population of genetically modified PD-L1+-expressing hematopoietic stem cells (HSCs), wherein the adult subject is not administered another immunosuppressive therapy.
Dependencies are inferred from the claim text.